The DOI matches its Crossref record.
Immunohistochemical Identification of Tumor Markers in Metastatic Adenocarcinoma:A Diagnostic Adjunct in the Determination of Primary Site
Open accessAbstract
Adenocarcinoma that metastasizes from an unknown primary site is a significant oncologic problem. With the exception of prostate-specific antigen and thyroglobulin, no single immunohistochemical marker is entirely site-specific. A retrospective study was undertaken to determine whether a panel of markers could accurately predict the site of origin of common metastatic adenocarcinomas. On the basis of reports of their relatively restricted specificity for carcinomas of colon, breast, lung, ovary, and upper gastrointestinal tract (stomach, pancreas, and bile duct), eight markers were selected for simultaneous evaluation: gross cystic disease fluid protein-15, breast cancer antigen 225 (BCA225), B72.3, DF3 (CA15-3), carcinoembryonic antigen (CEA), CA19-9, CA125, and estrogen receptor. The study population consisted of 128 metastatic nonmucinous adenocarcinomas for which the primary site was known. Staining was performed on formalin-fixed, paraffin-embedded tissue using an enhanced-sensitivity avidin-biotin peroxidase complex detection system. The most informative markers were CEA, CA19-9, CA125, and BCA225. With this four-marker panel, the most predictive multiple-marker phenotypes, as determined by a combination of area under the receiver operating characteristic curve, specificity, and percent correct predictions, were CEA+, BCA225-, and CA125- for colon tumors; BCA225+, CEA-, and CA125- for breast tumors; BCA225+, CEA+, and CA19-9- for lung tumors; CA125+ and CEA- for ovarian tumors; and CEA+, CA19-9+, and CA125+ for upper gastrointestinal tract tumors. Overall, these phenotypes correctly predicted the known primary site in 66% of cases. Until single highly sensitive and specific markers are developed for adenocarcinomas other than prostate and thyroid tumors, the origin of a metastatic adenocarcinoma can best be suggested or excluded with clinicopathologic data combined with a panel of selected immunohistochemical markers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Bussani, R., De-Giorgio, F., Abbate, A., & Silvestri, F. (2007) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.035105 · Cited by 642
Dennis, J. L., Hvidsten, T. R., Wit, E. C., Komorowski, J., Bell, A. K., Downie, I., Mooney, J., Verbeke, C., Bellamy, C., Keith, W. N., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2236 · Cited by 320
Value of Mesothelin Immunostaining in the Diagnosis of Mesothelioma
Ordóñez, N. G. (2003) · Modern Pathology · doi:10.1097/01.mp.0000056981.16578.c3 · Cited by 259
Abraham, J., Heimberger, A. B., Marshall, J., Heath, E., Drabick, J., Helmstetter, A., Xiu, J., Magee, D., Stafford, P., Nabhan, C., et al. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101016 · Cited by 47
Metadata
- Authors
- Brown, R. W., Campagna, L. B., Dunn, J. K., & Cagle, P. T.
- Venue
- American Journal of Clinical Pathology
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-01-01
- Volume
- 107
- Issue
- 1
- Pages
- 12-19
- ISSN
- 0002-9173 (ISSN-L)
- 1943-7722
- OpenAlex
- W60572870
- Cited by
- 169
- References
- 0
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunohistochemical Identification of Tumor Markers in Metastatic Adenocarcinoma:A Diagnostic Adjunct in the Determination of Primary Site. https://app.cochat.ai/papers/10.1093/ajcp/107.1.12
- The paper
- Brown, R. W., Campagna, L. B., Dunn, J. K., & Cagle, P. T. (1997). Immunohistochemical Identification of Tumor Markers in Metastatic Adenocarcinoma:A Diagnostic Adjunct in the Determination of Primary Site. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/107.1.12
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.